Prochymal^® Phase III Crohn's Disease Clinical Trial

enrollment to resume soon

Crohn's disease is a chronic, life-long condition with relapsing inflammation of the bowels and gastrointenstinal tract. Its fundamental cause is unknown, but it is suspected to come from a genetic predisposition of the body’s overreaction to the environment, items in the diet, or an infection. Severe Crohn's disease can cause pain, undesirable changes in lifestyle, hospitalizations, and side-effects from medications used for treatment. While Crohn's disease often first occurs in people between the ages of 20 and 30, it can occur in children or at any other age. In the majority of sufferers, it requires surgery at least once. Over 500,000 people in the U.S. are afflicted with Crohn's disease, and approximately 20,000 new cases are diagnosed each year.

The objective of the study is to establish the safety and durability of Prochymal in patients experiencing moderate-to-severe Crohn’s disease who are refractory to steroid, immunosuppressant, and biologic therapy.

Trial Overview

Click Here for more information

If you have questions about this clinical program, please email us at IBD@Osiris.com